It’s estimated that 90% of retail investors lose money. We help you beat those odds with concise research, education and more. Click here to see our offerings.
- A late-stage biopharma company focused on developing anti-cancer therapies
- Lead asset Motixafortide (BL-8040)= in P3 of development for stem-cell mobilization
- Motixafortide is also in P2 of development for acute myeloid leukemia (AML) and Pancreatic cancer
- Second asset AGI-134= entering P2 of development for treating solid tumors